Book chapter
Biparametric MRI of Prostate: Can We Shorten the MR Imaging Protocol?
Reading MRI of the Prostate, pp.49-58
Springer International Publishing
2020
DOI: 10.1007/978-3-319-99357-7_5
Abstract
According to the International Agency for Research on Cancer, annual incidence of cancer cases will be doubling by 2030 and prostate cancer is expected to be a major contributor. As of 2018, prostate cancer accounts for 20% of all male cancer cases and 9% of cancer related deaths. The ongoing challenges in the diagnosis and management of prostate cancer include identifying biologically significant disease at a stage while is still at a curative size and grade, while minimizing the detection of clinically insignificant cancers (Gleason score 3 + 3 = 6). The widespread adoption of prostate specific antigen (PSA) as a screening tool led to a decrease in prostate cancer mortality. However, there is concern that PSA screening has led to overdiagnosis and overtreatment of clinically insignificant prostate cancers.
Details
- Title: Subtitle
- Biparametric MRI of Prostate: Can We Shorten the MR Imaging Protocol?
- Creators
- Verena Obmann - University Hospital of BernAnanya Panda - Mayo Clinic in ArizonaVikas Gulani - University of Michigan–Ann Arbor
- Contributors
- Ananya Panda (Editor) - Mayo Clinic in ArizonaVikas Gulani (Editor) - University of Michigan–Ann ArborLee Ponsky (Editor)
- Resource Type
- Book chapter
- Publication Details
- Reading MRI of the Prostate, pp.49-58
- Publisher
- Springer International Publishing; Cham
- DOI
- 10.1007/978-3-319-99357-7_5
- Number of pages
- 10
- Language
- English
- Date published
- 2020
- Academic Unit
- Radiology
- Record Identifier
- 9984700443502771
Metrics
1 Record Views